BRCA1 mutations in women attending clinics that evaluate the risk of breast cancer.

BACKGROUND To define the incidence of BRCA1 mutations among patients seen in clinics that evaluate the risk of breast cancer, we analyzed DNA samples from women seen in this setting and constructed probability tables to provide estimates of the likelihood of finding a BRCA1 mutation in individual families. METHODS Clinical information, family histories, and blood for DNA analysis were obtained from 263 women with breast cancer. Conformation-sensitive gel electrophoresis and DNA sequencing were used to identify BRCA1 mutations. RESULTS BRCA1 mutations were identified in 16 percent of women with a family history of breast cancer. Only 7 percent of women from families with a history of breast cancer but not ovarian cancer had BRCA1 mutations. The rates were higher among women from families with a history of both breast and ovarian cancer. Among family members, an average age of less than 55 years at the diagnosis of breast cancer, the presence of ovarian cancer, the presence of breast and ovarian cancer in the same woman, and Ashkenazi Jewish ancestry were all associated with an increased risk of detecting a BRCA1 mutation. No association was found between the presence of bilateral breast cancer or the number of breast cancers in a family and the detection of a BRCA1 mutation, or between the position of the mutation in the BRCA1 gene and the presence of ovarian cancer in a family. CONCLUSIONS Among women with breast cancer and a family history of the disease, the percentage with BRCA1 coding-region mutations is less than the 45 percent predicted by genetic-linkage analysis. These results suggest that even in a referral clinic specializing in screening women from high-risk families, the majority of tests for BRCA1 mutations will be negative and therefore uninformative.

[1]  D. B. Berman,et al.  Frequency of recurrent BRCA1 and BRCA2 mutations in Ashkenazi Jewish breast cancer families , 1996, Nature Medicine.

[2]  F. Collins,et al.  The carrier frequency of the BRCA1 185delAG mutation is approximately 1 percent in Ashkenazi Jewish individuals , 1995, Nature Genetics.

[3]  E. Muir,et al.  Multiple primary carcinomata of the colon, duodenum, and larynx associated with kerato‐acanthomata of the face , 1967, The British journal of surgery.

[4]  M. King,et al.  Growth retardation and tumour inhibition by BRCA1 , 1996, Nature Genetics.

[5]  D. Berry,et al.  Probability of carrying a mutation of breast-ovarian cancer gene BRCA1 based on family history. , 1997, Journal of the National Cancer Institute.

[6]  D. Clayton,et al.  Germline mutations of the BRCA1 gene in breast and ovarian cancer families provide evidence for a genotype–phenotype correlation , 1995, Nature Genetics.

[7]  D. Bishop,et al.  Structure of the human MSH2 locus and analysis of two Muir-Torre kindreds for msh2 mutations. , 1994, Genomics.

[8]  M. Wolf,et al.  Gowden's disease. A cutaneous marker of breast cancer , 1978 .

[9]  W. Blattner,et al.  A cancer family syndrome in twenty-four kindreds. , 1988, Cancer research.

[10]  J. D. Thompson,et al.  BRCA1 mutations in a population-based sample of young women with breast cancer. , 1996, The New England journal of medicine.

[11]  M. Gail,et al.  Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. , 1989, Journal of the National Cancer Institute.

[12]  F. Couch,et al.  Mutations and Polymorphisms in the familial early‐onset breast cancer (BRCA1) gene , 1996, Human mutation.

[13]  M. Seller,et al.  Unusual case of Smith-Lemli-Opitz syndrome "type II". , 1995, American journal of medical genetics.

[14]  D. Easton,et al.  Genetic linkage analysis in familial breast and ovarian cancer: results from 214 families. The Breast Cancer Linkage Consortium. , 1993, American journal of human genetics.

[15]  M. Slattery,et al.  A comprehensive evaluation of family history and breast cancer risk. The Utah Population Database. , 1993, JAMA.

[16]  M. Skolnick,et al.  A collaborative survey of 80 mutations in the BRCA1 breast and ovarian cancer susceptibility gene. Implications for presymptomatic testing and screening. , 1995, JAMA.

[17]  Steven E. Bayer,et al.  A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. , 1994, Science.

[18]  P. Tonin,et al.  The genetic basis of Muir-Torre syndrome includes the hMLH1 locus. , 1996, American journal of human genetics.

[19]  Alfred A. Boyd,et al.  Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2 , 1996, Nature Genetics.

[20]  S. Seal,et al.  Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13. , 1994, Science.

[21]  Francis S. Collins,et al.  Mutations in the BRCA1 gene in families with early-onset breast and ovarian cancer , 1994, Nature Genetics.

[22]  D. Easton,et al.  Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. , 1995, American journal of human genetics.

[23]  Barbara L. Smith,et al.  Germ-line BRCA1 mutations in Jewish and non-Jewish women with early-onset breast cancer. , 1996, The New England journal of medicine.

[24]  D. Easton,et al.  Risks of cancer in BRCA1-mutation carriers , 1994, The Lancet.

[25]  J. Rommens,et al.  The complete BRCA2 gene and mutations in chromosome 13q-linked kindreds , 1996, Nature Genetics.

[26]  D. Bentley,et al.  Identification of the breast cancer susceptibility gene BRCA2 , 1995, Nature.

[27]  J. Manson,et al.  Family history, age, and risk of breast cancer. Prospective data from the Nurses' Health Study. , 1993, JAMA.

[28]  D J Prockop,et al.  Conformation-sensitive gel electrophoresis for rapid detection of single-base differences in double-stranded PCR products and DNA fragments: evidence for solvent-induced bends in DNA heteroduplexes. , 1993, Proceedings of the National Academy of Sciences of the United States of America.